TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +20.00%. A quarter ago, it was expected that this company would post a loss of $0.28 per share when it actually produced a loss of $0.28, delivering no surprise.Over the last four quarters, the company has surpa ...